Suzhou Fengbei Biotech Stock Co., Ltd. (SHA:603334)
China · Delayed Price · Currency is CNY 29.84
-0.82 (-2.67%)
Sep 11, 2026, 3:00 PM CST
SHA:603334 Revenue
Suzhou Fengbei Biotech Stock had revenue of 1.24B CNY in the quarter ending June 30, 2026, with 52.38% growth. This brings the company's revenue in the last twelve months to 4.04B, up 65.67% year-over-year. In the year 2025, Suzhou Fengbei Biotech Stock had annual revenue of 3.17B with 62.77% growth.
Revenue (ttm)
4.04B
Revenue Growth
+65.67%
P/S Ratio
1.06
Revenue / Employee
10.23M
Employees
395
Market Cap
4.28B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.17B | 1.22B | 62.77% |
| Dec 31, 2024 | 1.95B | 220.23M | 12.75% |
| Dec 31, 2023 | 1.73B | 19.09M | 1.12% |
| Dec 31, 2022 | 1.71B | 413.11M | 31.89% |
| Dec 31, 2021 | 1.30B | 505.78M | 64.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.